Ep 50. Modifiable risk factors and therapeutic targets in polymyalgia rheumatica

Update: 2025-06-12

Description

How can we identify modifiable risk factors and new therapeutic targets in polymyalgia rheumatica?

In this episode, recorded live at BSR25, Prof Ernest Choy and Dr Steven Zhao discuss Steven's genome-wide meta-analysis and Mendelian randomisation study. They cover the key findings, which include some novel loci and potential therapeutic targets for PMR, as well as the hallmarks of a good Mendelian randomisation study.

Further reading:

Read Steven's full study in Rheumatology

Thanks for listening to Talking Rheumatology Research! Join the conversation on X using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram and LinkedIn.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Comments

In Channel

Ep 51. Infliximab vs interferon-α in the treatment of Behçet’s syndrome: clinical data from the BIO-BEHÇET’S randomized controlled trial

2025-08-1308:54

Ep 50. Modifiable risk factors and therapeutic targets in polymyalgia rheumatica

2025-06-1210:10

Ep 49. Improving time to diagnosis in axial spondyloarthritis

2025-05-0811:33

Ep 48. Deciphering difficult-to-treat psoriatic arthritis

2024-10-2418:24

Ep 47. Relapse after cessation of weekly tocilizumab for giant cell arteritis

2024-08-2511:20

Ep 46. Patient involvement in Rheumatology research

2024-07-1122:13

Ep 45. Community awareness of childhood arthritis in the UK

2024-06-1310:22

Ep 44. Neuropsychiatric symptoms in systemic autoimmune rheumatic diseases

2024-05-2313:23

Ep 43. The metaverse: a new frontier for rheumatology

2024-04-1012:04

Ep 42. Combination therapy or autologous hematopoietic stem cell transplantation for patients with progressive systemic sclerosis?

2024-01-1118:41

Ep 41. Addressing the leaky pipeline

2024-01-0418:44

Ep 40. New Editor-in-Chief: Introducing Prof Ernest Choy

2023-12-2105:30

Ep 39. UK JIA Biologics Register: stopping biologics for remission

2023-11-3010:55

Ep 38. Is risankizumab safe and effective for active psoriatic arthritis? Results from the KEEPsAKE 2 study

2023-10-2608:07

Ep 37. Can MSUS and RADAI-F5 help to identify RA patients at risk of poor functional and radiological outcomes?

2023-10-1813:33

Ep 36. Trainee Publishing Programme 2023: Dr Charlotte Sharp & Karen Staniland

2023-10-1119:51

Ep 35. Trainee Publishing Programme 2023: Dr Pallavi Shamdasani

2023-10-0418:55

Ep 34. Trainee Publishing Programme 2023: Dr Shivani Gor & Dr Sung-Hee Kim

2023-09-2717:22

Ep 33. Trainee Publishing Programme 2023: Dr Lauren Huckerby

2023-09-2017:06

Ep 32. Trainee Publishing Programme 2023: Dr Cristiana Sieiro Santos

2023-09-1312:10

00:00

Ep 50. Modifiable risk factors and therapeutic targets in polymyalgia rheumatica

British Society for Rheumatology

#box-pro-ellipsis-176336642633841{-webkit-line-clamp:2;}Ep 50. Modifiable risk factors and therapeutic targets in polymyalgia rheumatica

Ep 50. Modifiable risk factors and therapeutic targets in polymyalgia rheumatica

British Society for Rheumatology

Ep 50. Modifiable risk factors and therapeutic targets in polymyalgia rheumatica